Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.67 EUR | 0.00% | +10.79% | +1.91% |
24/05 | Innate Pharma: five abstracts selected for ASCO | CF |
14/05 | Transcript : Innate Pharma S.A., Q1 2024 Earnings Call, May 14, 2024 |
Sales 2024 * | 47.51M 51.54M 4.28B | Sales 2025 * | 74.4M 80.71M 6.71B | Capitalization | 216M 234M 19.46B |
---|---|---|---|---|---|
Net income 2024 * | -24M -26.04M -2.16B | Net income 2025 * | -21M -22.78M -1.89B | EV / Sales 2024 * | 2.99 x |
Net cash position 2024 * | 73.78M 80.05M 6.65B | Net cash position 2025 * | 131M 142M 11.82B | EV / Sales 2025 * | 1.14 x |
P/E ratio 2024 * |
-21.4
x | P/E ratio 2025 * |
4.41
x | Employees | 179 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.91% |
Latest transcript on Innate Pharma
1 week | +10.79% | ||
Current month | +21.09% | ||
1 month | +18.93% | ||
3 months | +11.25% | ||
6 months | +16.09% | ||
Current year | +1.91% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Vivier
FOU | Founder | 60 | 23/99/23 |
Chief Executive Officer | 62 | 23/99/23 | |
Frederic Lombard
DFI | Director of Finance/CFO | 49 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 23/99/23 | |
Gilles Brisson
BRD | Director/Board Member | 72 | 26/07/26 |
Olivier Martinez
BRD | Director/Board Member | 54 | 25/10/25 |
Date | Price | Change | Volume |
---|---|---|---|
24/24/24 | 2.67 | 0.00% | 157,426 |
23/24/23 | 2.67 | -2.55% | 195,794 |
22/24/22 | 2.74 | +7.24% | 270,698 |
21/24/21 | 2.555 | -2.85% | 194,610 |
20/24/20 | 2.63 | +9.13% | 401,410 |
Real-time Euronext Paris, May 24, 2024 at 09:05 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.91% | 234M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- IPH Stock